AKRO vs. CRVS

Last updated Jun 6, 2026

AKRO (Akero Therapeutics, Inc.) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.22 correlation, their price movements are largely independent.

Performance

AKRO vs. CRVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Akero Therapeutics, Inc. (AKRO) and Corvus Pharmaceuticals, Inc. (CRVS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

AKRO

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CRVS

• 1D: 1.03%
• 1M: -25.35%
• YTD: 52.21%
• 6M: 33.03%
• 1Y: 212.53%
• 3Y*: 52.88%
• 5Y*: 34.23%
• 10Y*: -1.93%

*Multi-year figures are annualized to reflect compound growth (CAGR)

AKRO vs. CRVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
AKRO Akero Therapeutics, Inc.	0.00%	96.44%	19.14%	-57.39%	159.10%	-18.02%	16.24%	21.15%
CRVS Corvus Pharmaceuticals, Inc.	52.21%	43.93%	203.98%	107.06%	-64.73%	-32.30%	-34.56%	50.69%

Correlation

The correlation between AKRO and CRVS is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.26
Correlation (All Time) Calculated using the full available price history since Jun 21, 2019	0.22

The correlation between AKRO and CRVS shifts across timeframes, from 0.11 (1 year) to 0.26 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap AKRO : $4.48B CRVS : $1.05B
EPS AKRO : -$3.58 CRVS : -$0.53
PB Ratio AKRO : 4.68 CRVS : 4.38
Total Revenue (TTM) AKRO : $0.00 CRVS : $0.00
Gross Profit (TTM) AKRO : $0.00 CRVS : -$26.00K
EBITDA (TTM) AKRO : -$288.18M CRVS : -$47.43M

Return for Risk

AKRO vs. CRVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRVS

CRVS Risk / Return Rank: 87
CRVS Sharpe Ratio Rank: 76
CRVS Sortino Ratio Rank: 96
CRVS Omega Ratio Rank: 93
CRVS Calmar Ratio Rank: 87
CRVS Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AKRO vs. CRVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Akero Therapeutics, Inc. (AKRO) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	AKRO	CRVS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.18	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.26	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.02	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.02	—

Drawdowns

Drawdown Indicators

	AKRO	CRVS	Difference
Max Drawdown Largest peak-to-trough decline	—	-96.97%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-54.94%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-72.02%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-92.40%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-96.97%	—
Current Drawdown Current decline from peak	—	-54.08%	—
Average Drawdown Average peak-to-trough decline	—	-69.33%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	24.56%	—

Volatility

Volatility by Period

	AKRO	CRVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	23.73%	—
Volatility (6M) Calculated over the trailing 6-month period	—	111.90%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	180.94%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	131.04%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	111.13%	—

Dividends

AKRO vs. CRVS - Dividend Comparison

Neither AKRO nor CRVS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both AKRO and CRVS in my portfolio?

AKRO and CRVS have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.